Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.69 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.69 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.69 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 5/20 | 0.57 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.50 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.50 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2548737 | 1.00 | KCNH2 (0.69) | KCNH2SLC6A4SLC6A2SLC6A3KCNJ1 | |
| SCHEMBL2549429 | 0.98 | KCNH2 (0.71) | KCNH2SLC6A4SLC6A2SLC6A3KCNJ1 | |
| SCHEMBL5752571 | 0.92 | KCNH2 (0.64) | KCNH2SLC6A4SLC6A2SLC6A3KCNJ1 | |
| SCHEMBL5754907 | 0.88 | SIGMAR1 (0.70) | KCNH2SLC6A4SLC6A2SLC6A3KCNJ1 | |
| SCHEMBL10507686 | 0.86 | SIGMAR1 (0.63) | KCNH2SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL14486498 | 0.82 | SIGMAR1 (0.66) | KCNH2SLC6A4SLC6A2SLC6A3KCNJ1 | |
| Hydrochloric Acid SCHEMBL3062972 | 0.81 | CXCR4 (0.66) | KCNH2SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2195558 | 0.81 | SIGMAR1 (0.77) | KCNH2SLC6A4SLC6A3KCNJ1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6291076 | 0.81 | CXCR4 (0.66) | KCNH2SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL16739273 | 0.81 | SIGMAR1 (0.77) | KCNH2SLC6A4SLC6A3KCNJ1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024023284-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2024-02-01 | — | — | WO | disclosed |
| US-9808456-B2 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease | REMYND NV (BE) | 2017-11-07 | — | — | US | disclosed |
| US-20160101102-A1 | PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE | REMYND NV (BE) | 2016-04-14 | — | — | US | disclosed |
| EP-2744798-B1 | PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE | REMYND NV (BE) | 2016-03-30 | — | — | EP | disclosed |
| US-9187440-B2 | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease | REMYND NV (BE) | 2015-11-17 | — | — | US | disclosed |
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013024168-A1 | PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE | REMYND NV (BE) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013004642-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2013-01-10 | — | — | WO | disclosed |
| US-7312342-B2 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)-methanone and salts thereof | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2007-12-25 | — | — | US | disclosed |
| EP-1353906-B1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GMBH (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-20040063723-A1 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| EP-1353906-A1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GmbH (DE) | 2003-10-22 | — | — | EP | disclosed |
| CN-1394203-A | As 5-HT2APiperidine and piperazine derivatives of receptor antagonists | MERCK PATENT GMBH (DE) | 2003-01-29 | — | — | CN | disclosed |
| WO-2002059092-A1 | PROCESS FOR THE PREPARATION OF (3-CYANO-1H-INDOL-7-YL)(4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL)-METHANONE AND SALTS THEREOF | MERCK PATENT GMBH (DE) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101102-A1 | PIPERAZINE THIAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF TAUOPATHIES SUCH AS ALZHEIMER'S DISEASE | MAPT, PSEN1, RTN3 | KCNH2 1993/4885SLC6A4 1934/4885SLC6A2 1188/4885 |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | KCNH2 2629/4885SLC6A4 2790/4885SLC6A2 1629/4885 |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | KCNH2 144/4885SLC6A4 1793/4885SLC6A2 747/4885 |
| US-20040063723-A1 | Process for the preparation of (3-cyano-1h-indol-7-yl) (4-(4-fluorophenethyl) piperazin-1-yl)- methanone and salts thereof | TPH1, TPH2, IDO1 | KCNH2 153/4885SLC6A4 118/4885SLC6A2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.